期刊文献+

卵巢上皮性肿瘤腹水的治疗现状及进展 被引量:3

原文传递
导出
摘要 多数卵巢上皮性癌、输卵管癌及原发腹膜癌患者就诊时合并恶性腹水,其初始治疗以原发肿瘤手术和紫杉醇联合铂类化疗为主,且病情多缓解,但一旦铂类化疗耐药,则治疗棘手。目前其治疗手段包括利尿剂、腹腔化疗和细胞因子等,但疗效不定。随着对恶性腹水的病理生理机制研究和新药物的研发,例如血管内皮生长因子(VEGF)抑制剂、Catumaxomab抗体和中成药等在恶性腹水治疗取得一定疗效。对于一些晚期恶性腹水,应采取个体化的多种综合治疗措施,在提高疗效的同时,关注患者生活质量为目标。
出处 《中国妇产科临床杂志》 2014年第2期189-192,共4页 Chinese Journal of Clinical Obstetrics and Gynecology
  • 相关文献

参考文献23

  • 1Adam RA, Adam YG. Malignant ascites: past, present,and future. J Am Coll Surg, 2004,198: 999 - 1011.
  • 2Kipps E,Tan DS,Kaye SB. Meeting the challenge of ascitesin ovarian cancer; new avenues for therapy and research. NatRev Cancer, 2013,13: 273 - 282.
  • 3Smith EM, Jayson GC. The current and future managementof malignant ascites. Clin Oncol (R Coll Radiol), 2003,15:59 - 72.
  • 4Kerr EH, Frederick PJ, Egger ME, et al. Lung resistance -related protein (LRP) expression in malignant ascitic cells asa prognostic marker for advanced ovarian serous carcinoma.Ann Surg Oncol,2013,20: 3059 - 3065.
  • 5Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial ofbevacizumab in ovarian cancer. N Engl J Med, 2011, 365 :2484- 2496.
  • 6Burger RA, Brady MF, Bookman MA, et al. Incorporationof bevacizumab in the primary treatment of ovarian cancer.N Engl J Med, 2011,365: 2473- 2483.
  • 7Kristensen G. Result of interim analysis of overall survival inthe GCIG ICON7 phase 瓜 randomized trial of bev - acizumabin women with newly diagnosed ovarian cancer. J Clin On-col, 2011, 29: 781.
  • 8Aghajanian C,Blank SV, Goff BA,et al. OCEANS: a ran-domized ,double - blind, placebo - controlled phase 瓜 trial ofchemotherapy with or without bevacizumab in patients withplatinum - sensitive recurrent epithelial ovarian,primary per-itoneal, or fallopian tube cancer. J Clin Oncol, 2012,30:2039- 2045.
  • 9Pujade - Lauraine E, Hilpert F, Weber B, et al. AURELIA:A randomized phase IH trial evaluating bevacizumab pluschemotherapy for platinum - resistant recurrent ovarian canc-er. J Clin Oncol, 2012, 30 (suppl) LBA5002.
  • 10Stark D, Nankivell M, Pujade - Lauraine E, et al. Standardchemotherapy with or without bevacizumab in advanced ovar-ian cancer: quality - of - life outcomes from the InternationalCollaboration on Ovarian Neoplasms (ICON7) phase 3 ran-domised trial. Lancet Oncol, 2013, 14: 236 - 243.

二级参考文献29

  • 1蔡艳军,郑大勇,罗荣城,陈锦章,李爱民,席箐乐,丁雪梅.Avastin联合顺铂对VEGF高表达的荷卵巢癌裸鼠腹水的抑制作用[J].南方医科大学学报,2007,27(5):647-649. 被引量:9
  • 2Kesterson JP, Mhawech-Fauceglia P, Lele S.The use of bevacizumab in refractory ovarian granulosa-cell carcinoma with symptomatic relief of ascites: a case report [J]. Gynecol Oncol, 2008, 111 (3): 527-9.
  • 3Shichiri M, Hirata Y. Antiangiogenesis signals by endostatin [J]. FASEB J, 2001,15 (6): 1044-53.
  • 4Xu F, Ma Q, Sha H. Optimizing drug delivery for enhancing therapeutic efficacy of recombinant human endostatin in cancer treatment [J]. Crit Rev Ther Drug Carrier Syst, 2007, 24 (5): 445-92.
  • 5Velde EA, Reijerkerk A, Brandsma D, et al. Early endostatin treatment inhibits metastatic seeding of murine colorectal cancer cells in the liver and their adhesion to endothelial cells [J]. Br J Cancer, 2005, 92(4): 729-35.
  • 6Manuela C, Patrizia M, Alberto G, et al. Continuous infusion of Endostatin inhibits differen-tiation, mobilization, and clonoganic potential of endothelial cell progenitors [ J ]. Clin Cancer Res, 2003, 9(1): 377-82.
  • 7Kisker O, Becker CM, Prox D et al. Continuous administration of endostatin by intraperito-neally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xeno-graft tumor model [ J ]. Cancer Res, 2001, 61 (20): 7669-74.
  • 8Pourgholami MH, Yah Cai Z, Lu Y, et al. Albendazole:a potent inhibitor of vascular endothelial growth factor and malignant ascites formation in OVCAR-3 tumor-bearing nude mice [J]. Clin Cancer Res, 2006, 12(6): 1928-35.
  • 9Tamsma J. The pathogenesis ofascites [J]. Cancer Treat Res, 2007, 134: 109-18.
  • 10Becker G, Galandi D, Blum HE. Malignant ascites: systematic review and guideline for treatment[J]. Eur J Cancer, 2006, 42(5): 589-97.

共引文献39

同被引文献28

引证文献3

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部